Is tapentadol different from classical opioids? A review of the evidence

British Journal of Pain

Volumn 10, Issue 4, 2016, Pages 217-221

  Langford, Richard M ^a   Knaggs, Roger ^b   Farquhar Smith, Paul ^c   Dickenson, Anthony H ^d  

^a BARTS HEALTH NHS TRUST   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

analgesic mechanisms of action; analgesics; opioids; pain pharmacology; Tapentadol

Indexed keywords

ALFENTANIL; DEXTROPROPOXYPHENE; DIAMORPHINE; FENTANYL; HYDROMORPHONE; METHADONE; MONOAMINE; NALOXONE; OPIATE; OXYCODONE; REMIFENTANIL; TAPENTADOL;

ANDROGEN DEFICIENCY; ARTICLE; BONE PAIN; CHRONIC PAIN; DRUG STRUCTURE; HUMAN; LOW BACK PAIN; NEUROPATHIC PAIN; NONHUMAN; PAIN; PAIN ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNSPECIFIED SIDE EFFECT;

EID: 84992650049     PISSN: 20494637     EISSN: 20494645     Source Type: Journal    
DOI: 10.1177/2049463716657363     Document Type: Article

References (21)

1. Drewes AM, Jensen RD, Nielsen LM. Differences between opioids: pharmacological, experimental, clinical and economical perspectives. Br J Clin Pharmacol 2013; 75(1): 60–78.
2. Raffa RB, Buschmann H, Christoph T. Mechanistic and functional differentiation of tapentadol and tramadol. Expert Opin Pharmacother 2012; 13(10): 1437–1449.
3. Hahn M. Three-dimensional shape-based searching of conformationally flexible compounds. J Chem Inf Comput Sci 1997; 37: 80–86.
4. Manglik A, Kruse AC, Kobilka TS. Crystal structure of the µ-opioid receptor bound to a morphinan antagonist. Nature 2012; 485(7398): 321–326.
5. Bannister K, Bee LA, Dickenson AH. Preclinical and early clinical investigations related to monoaminergic pain modulation. Neurotherapeutics 2009; 6(4): 703–712.
6. Christoph T, Schroder W, Tallarida RJ. Spinal-supraspinal and intrinsic mu-opioid receptor agonist-norepinephrine reuptake inhibitor (MOR-NRI) synergy of tapentadol in diabetic heat hyperalgesia in mice. J Pharmacol Exp Ther 2013; 347(3): 794–801.
7. Tzschentke TM, Christoph T, Schröder W. Tapentadol: with two mechanisms of action in one molecule effective against nociceptive and neuropathic pain: preclinical overview. Schmerz 2011; 25: 19–25.
8. Kogel B, De VJ, Tzschentke TM. The antinociceptive and antihyperalgesic effect of tapentadol is partially retained in OPRM1 (mu-opioid receptor) knockout mice. Neurosci Lett 2011; 491(2): 104–107.
9. Bannister K, Patel R, Goncalves L. DNIC and nerve injury: restoring an imbalance between descending monoamine inhibitions and facilitations. Pain 2015; 156(9): 1803–1811.
10. Niesters M, Proto PL, Aarts L. Tapentadol potentiates descending pain inhibition in chronic pain patients with diabetic polyneuropathy. Br J Anaesth 2014; 113(1): 148–156.
11. Lange B, Kuperwasser B, Okamoto A. Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv Ther 2010; 27(6): 381–399.
12. Sánchez Del Águila MJ, Schenk M, Kern KU. Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain. Clin Ther 2015; 37: 94–113.
13. Schwartz S, Etropolski M, Shapiro DY. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin 2011; 27(1): 151–162.
14. Freynhagen R, Baron R, Gockel U. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006; 22(10): 1911–1920.
15. Baron R, Likar R, Martin-Mola E. Effectiveness of tapentadol prolonged release (PR) compared with oxycodone/naloxone PR for the management of severe chronic low back pain with a neuropathic component: a randomized, controlled, open-label, phase 3b/4 study. Pain Practice 2016; 16: 580–599.
16. Baron R, Jansen J-P, Binder A. Tolerability, safety, and quality of life with tapentadol prolonged release (PR) compared with oxycodone/naloxone PR in patients with severe chronic low back pain with a neuropathic component: a randomized, controlled, open-label, phase 3b/4 trial. Pain Practice 2016; 16: 600–619.
17. Daniels SE, Golf M. Clinical efficacy and safety of tapentadol immediate release in the postoperative setting. J Am Podiatr Med Assoc 2012; 102(2): 139–148.
18. Stegmann JU, Weber H, Steup A. The efficacy and tolerability of multiple-dose tapentadol immediate release for the relief of acute pain following orthopedic (bunionectomy) surgery. Curr Med Res Opin 2008; 24(11): 3185–3196.
19. Mercadante S, Porzio G, Gebbia V. New opioids. J Clin Oncol 2014; 32(16): 1671–1676.
20. Dart RC, Cicero TJ, Surratt HL. Assessment of the abuse of tapentadol immediate release: the first 24 months. J Opioid Manag 2012; 8(6): 395–402.
21. Dart RC, Adams E, Bucher Bartelson B. Trends in the non-medical use of tapentadol immediate release by college students. In: American academy of pain medicine (AAPM), Palm Springs, CA, 23–26 February 2012.